Scilex Holding (SCLXW) EBITDA (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly EBITDA of -$32.2 million in Q1 2026, up 19.45% quarter-over-quarter from -$39.9 million in Q4 2025, and down 15.31% on a YoY basis from -$38.0 million in Q1 2025.
Scilex Holding (SCLXW) EBITDA (2020 - 2026) Analysis & Trends
Scilex Holding's EBITDA history runs 7 years deep, the most recent figure standing at -$32.2 million for Q1 2026.
- In Q1 2026, EBITDA fell 15.31% year-over-year to -$32.2 million; the TTM figure through Mar 2026 stood at -$376.9 million (down 438.41% YoY), while the FY2025 annual figure was -$370.9 million, down 457.76% from the prior year.
- EBITDA was -$32.2 million for Q1 2026 at Scilex Holding, up from -$39.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.2 million in Q3 2024 to a low of -$260.8 million in Q3 2025.
- Historically, EBITDA has averaged -$36.8 million across 5 years, with a median of -$25.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: EBITDA surged 96.54% in 2024, then plunged 21136.97% in 2025.
- A 5-year view of EBITDA shows it stood at -$19.7 million in 2022, then decreased by 8.4% to -$21.4 million in 2023, then surged by 75.92% to -$5.2 million in 2024, then plunged by 674.85% to -$39.9 million in 2025, then climbed by 19.45% to -$32.2 million in 2026.
- The last three EBITDA figures came in at -$32.2 million (Q1 2026), -$39.9 million (Q4 2025), and -$260.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.83 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -32.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.17 Mn |
| Dec 31, 2025 | -39.94 Mn |
| Sep 30, 2025 | -260.79 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -27.90 Mn |
| Dec 31, 2024 | -5.15 Mn |
| Sep 30, 2024 | -1.23 Mn |
| Jun 30, 2024 | -35.73 Mn |
| Mar 31, 2024 | -19.48 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -25.47 Mn |
| Dec 31, 2022 | -19.74 Mn |
| Sep 30, 2022 | -10.62 Mn |
| Jun 30, 2022 | -11.47 Mn |
| Mar 31, 2022 | -8.81 Mn |
| Dec 31, 2021 | -35.22 Mn |
| Sep 30, 2021 | -283,346.00 |
| Jun 30, 2021 | -172,140.00 |